

# III конгрес по превентивна медицина на Македонија со меѓународно учество

МЛД

Р 333

ИНФОРМАЦИИ

КОНТАКТ

III конгрес на превентивна медицина 04-07.10.2006

## УПРАВУВАЊЕ

- + Добредојдовте
- + Одбори
- + Информации и вести
- + Важни дати
- + Програма
- + Распоред по време
- + Листа на автори
- + Сместување
- + Презентации
- + Контакт
- + Одјава



English

## Апстракт преглед

Останува: -1-1-1 дена и 06:57:45 часа!  
dr Smokovski Ivica

### Преглед на апстракти

Апстракт

[Назад во апстракт преглед](#)

Дата на пријавување	2006-05-31 22:22:38
Тема	Незаразни заболувања - превенција и контрола
Тип на презентација	Постер презентација
Наслов	<b>Comparison of type 2 diabetic subjects identified for CHD primary prevention with statins by Adult Treatment Panel III Guidelines and Framingham model</b>
Автори	Ivica Smokovski 1
Институции	1 Novo Nordisk A/S Representative Office Macedonia
Содржина	<p>Purpose: To determine the difference between number of type 2 diabetic subjects identified for Coronary Heart Disease (CHD) primary prevention with statins by Framingham model for calculation of 10-year CHD absolute risk and Adult Treatment Panel (ATP) III Guidelines. Material and Methods: Cohort of 516 type 2 diabetic subjects with no arterial disease (CHD, cerebrovascular disease or peripheral arterial disease), no prior hypolipemic treatment, aged 30-65 years, receiving insulin treatment for 6 months, was included in analysis. Subjects were identified for CHD primary prevention with statin if LDL Cholesterol was higher than 2.6 mmol/l according to ATP III Guidelines, and if 10-year CHD absolute risk was higher than 15% accompanied by Total Cholesterol higher than 5.0 mmol/l according to Framingham model. Results: Out of 516 subjects, 113 were not identified and 174 were identified for primary prevention with both methods. In addition, 58 subjects were identified for primary prevention only with Framingham model, and 171 were identified for primary prevention only with ATP III. Overall, 232 subjects were identified with Framingham model, and 345 were identified with ATP III (<math>p &lt; 0.001</math>). Conclusion: CHD primary prevention with statin should be initiated in majority of type 2 diabetic subjects, whereas ATP III Guidelines identify significantly more subjects for primary prevention with statins compared to Framingham model having both clinical and health economics implications.</p>
Клучни зборови	type 2 diabetes, CHD , primary prevention